Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology

Respir Res. 2023 Nov 6;24(1):271. doi: 10.1186/s12931-023-02575-3.

Abstract

Introduction: Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associated with worse clinical outcome. Electronic nose (eNose) sensor technology profiles volatile organic compounds in exhaled breath and has potential to detect ILD non-invasively. We assessed the accuracy of differentiating breath profiles of patients with ILD from patients with asthma, chronic obstructive pulmonary disease (COPD), and lung cancer using eNose technology.

Methods: Patients with ILD, asthma, COPD, and lung cancer, regardless of stage or treatment, were included in a cross-sectional study in two hospitals. Exhaled breath was analysed using an eNose (SpiroNose) and clinical data were collected. Datasets were split in training and test sets for independent validation of the model. Data were analyzed with partial least squares discriminant and receiver operating characteristic analyses.

Results: 161 patients with ILD and 161 patients with asthma (n = 65), COPD (n = 50) or lung cancer (n = 46) were included. Breath profiles of patients with ILD differed from all other diseases with an area under the curve (AUC) of 0.99 (95% CI 0.97-1.00) in the test set. Moreover, breath profiles of patients with ILD could be accurately distinguished from the individual diseases with an AUC of 1.00 (95% CI 1.00-1.00) for asthma, AUC of 0.96 (95% CI 0.90-1.00) for COPD, and AUC of 0.98 (95% CI 0.94-1.00) for lung cancer in test sets. Results were similar after excluding patients who never smoked.

Conclusions: Exhaled breath of patients with ILD can be distinguished accurately from patients with other respiratory diseases using eNose technology. eNose has high potential as an easily accessible point-of-care medical test for identification of ILD amongst patients with respiratory symptoms, and could possibly facilitate earlier referral and diagnosis of patients suspected of ILD.

Keywords: Biomarker; Breath test; Diagnostic test; Electronic nose; Interstitial lung diseases; Lung cancer; Obstructive lung disease.

MeSH terms

  • Asthma* / diagnosis
  • Breath Tests / methods
  • Cross-Sectional Studies
  • Electronic Nose
  • Exhalation
  • Humans
  • Lung Diseases, Interstitial*
  • Lung Neoplasms*
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Respiration Disorders*
  • Volatile Organic Compounds*

Substances

  • Volatile Organic Compounds